Name: 글로벌 시장 동향
SKU: BT7599
Availability: InStock

보고서 요약(국문)

개요
글로벌 첨단 치료 의약품(ATMP) 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 기록하며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
첨단 치료 의약품(ATMP)은 유전자, 조직 또는 세포를 기반으로 생산되는 의약품으로, 질병 및 부상 치료에 새로운 가능성을 제시합니다. ATMP는 유전자 치료제, 체세포 치료제, 조직 공학 의약품으로 분류됩니다.
첨단 치료 의약품(ATMP)은 연구 중심의 다양한 생물 의약품을 아우르는 혁신적인 제품군입니다. 이러한 의약품은 세포 치료 및 유전자 치료를 기반으로 하며, 의료 기기와 결합된 치료법은 조직 공학 제품이라고 합니다.

시장 동향: 성장 동인 및 제약 요인
연구 개발 활동 증가
유전 질환 치료에 대한 새로운 접근 방식의 증가와 신약 및 치료법 개발 연구에 대한 투자 증가는 시장 성장을 견인할 것으로 예상됩니다.
예를 들어, 미국 국립과학공학통계센터(NCSE)에 따르면, 2022년 학술 기관의 연구 개발 지출은 총 978억 달러로, 2021년 대비 80억 달러 증가한 것으로 추산됩니다.
또한, Urgo는 1억 700만 달러 규모의 인공 피부 공학 연구소를 설립하여 의료 전문가들이 심각한 상처를 효과적으로 치료하고 환자를 신속하게 회복시킬 수 있도록 인공 피부를 개발하는 혁신적인 조직 공학 연구소를 운영하고 있습니다. 이처럼 연구 활동 증가와 신제품 출시를 위한 투자 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.
제약 요인
엄격한 승인 규제
의약품 승인과 관련된 엄격한 규제는 시장 성장을 저해할 것으로 예상됩니다. 유전자 교정 및 치료와 관련된 위험 또한 시장 성장을 저해하는 요인입니다.

시장 세분화 분석
전 세계 첨단 치료 의약품(ATMP) 시장은 유형, 질병 적응증 및 지역별로 세분화됩니다.
유전자 치료제 부문은 시장 점유율의 49.5%를 차지했습니다.
유전자 치료제는 유전 질환의 증가와 이러한 질환을 치료하는 데 있어 효과적인 치료법으로 인해 시장에서 지배적인 위치를 차지하고 있습니다. siRNA, shRNA, 안티센스 올리고뉴클레오티드, CRISPR/Cas9 시스템, 플라스미드 DNA, miRNA와 같은 유전자 치료제는 생의학 분야에서 큰 잠재력을 보여주고 있습니다.
유전자 치료는 기능하는 유전자를 신체의 특정 조직에 전달하여 결핍되거나 기능하지 않는 단백질을 생성하는 차세대 의학입니다. 개인의 세포와 유전자에 따라 잘못된 유전자를 표적으로 하는 약물이 생산됩니다. 대부분의 질병은 유전자 치료제를 통해 치료하거나 예방할 수 있습니다.

예를 들어, 2021년 NIH 보고서에 따르면 유전자 치료 의약품 관리는 다양한 치료 용도에서 30~40%의 완전 관해율과 50~60%의 부분 관해율을 보였으며, 총 관해율은 90~96%에 달하는 것으로 추정됩니다. 따라서 위의 요인들이 해당 부문의 시장 점유율을 주도하는 데 기여할 것으로 예상됩니다.
지리적 분석
북미는 전 세계 첨단 치료 의약품(ATMP) 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
북미는 유전 질환의 증가로 인해 시장 점유율에서 주도적인 위치를 차지할 것으로 예상됩니다. 이 지역의 유전 질환 증가는 연구를 촉진하고 신약 개발의 길을 열어주고 있습니다.
예를 들어, 2022년 CDC 보고서에 따르면 낭포성 섬유증(CF)은 호흡 및 소화 문제를 일으키는 유전 질환입니다. 미국에서는 약 35,000명이 CF를 앓고 있습니다. 미국에서는 매년 약 1,000건의 새로운 낭포성 섬유증(CF) 사례가 진단됩니다.
또한, 연구자들은 미국 내 남성 약 18,000명이 혈우병을 앓고 있다고 추정했습니다. 이들 중 약 3분의 2는 미국 내 전문적이고 포괄적인 혈우병 치료 센터(HTC) 네트워크에서 치료를 받았습니다. 따라서 위의 요인들이 예측 기간 동안 해당 지역 시장 성장을 견인할 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19는 시장 성장에 중간 정도의 영향을 미쳤습니다. COVID-19 기간 동안 연구 개발 활동이 감소했는데, 이는 COVID-19 치료를 위한 신약 개발에 대한 관심과 필요성이 증가했기 때문입니다. 또한, 봉쇄 기간 동안 공급망이 중단되었습니다.

시장 세분화
유형별
• 유전자 치료제
• 체세포 치료제
• 조직 공학 의약품
적응증별
• 암
• 심혈관 질환
• 근골격계 질환
• 면역계 및 염증 질환
• 신경계 질환
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽 지역
• 남미
o 브라질
o 아르헨티나
o 기타 남미 지역
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양 지역
• 중동 및 아프리카
경쟁 환경
주요 기업으로는 RHEACELL, BioTissue Technologies GmbH, Mukocell GmbH, Orchard Therapeutics plc., Kite Pharma EU B.V., Bristol-Myers Squibb Pharma EEIG, Novartis Europharm Limited 등이 있으며, 이들 기업은 상당한 시장 점유율을 차지하고 있습니다. 암젠 유럽 B.V.를 비롯한 여러 기업이 포함됩니다.

보고서 구매 이유:

• 유형, 질병 적응증, 지역별 글로벌 첨단 치료 의약품(ATMP) 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 첨단 치료 의약품 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품을 모두 포함하는 제품 매핑 엑셀 파일을 제공합니다.

글로벌 첨단 치료 의약품 시장 보고서는 약 47개의 표, 48개의 그림, 176페이지로 구성됩니다.
2023년 주요 고객
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Advanced Therapy Medicinal Product(ATMP) Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Advanced therapy medicinal products (ATMPs) are medicines that are produced based on genes, tissues, or cells. They offer new opportunities for the treatment of disease and injury. The ATMPs are classified into gene therapy medicines, somatic cell therapy medicines, and tissue-engineered medicines.
Advanced therapy medicinal products (ATMPs) constitute an innovative class of heterogeneous research-driven biopharmaceuticals. The drugs are based on cell therapy and gene therapy, the therapies in combination with medical devices are called tissue-engineered products.
Market Dynamics: Drivers & Restraints
The increase in the number of research and developmental activities
The increase in the novel approaches to treating genetic disorders and increased investments in the research for developing new drugs and treatment procedures is expected to drive the market growth.
For instance, according to the National Center for Science and Engineering Statistics, it is estimated that Research and development spending by academic institutions totaled $97.8 billion in 2022, an increase of $8.0 billion from 2021
For instance, Urgo launched a $107M artificial skin engineering laboratory novel tissue engineering laboratory to create artificial skin to help the health care professionals in the effective treatment of severe wounds and quickly curing patients. Thus, the increasing research and increase in investments in introducing new products are expected to drive market growth in the forecast period.
Restraint
Stringent regulations for the approvals
The stringent regulations associated with the approvals of the medicine are expected to decline the market growth. The risks associated with gene corrections and treatments are also a factor that hamper market growth.
Segment Analysis
The global advanced therapy medicinal product (ATMP) market is segmented based on type, disease indication, and region.
Gene therapy medicines segment accounted for 49.5% of the market share
Gene therapy medicines have been holding a dominant position in the market share. This is due to the increase in genetic disorders and also the efficiency of the treatment to treat the disorder. Gene therapy drugs such as siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid DNA, and miRNA have shown great potential in biomedical applications.
Gene therapy is a new generation of medicine where a functioning gene is delivered to a targeted tissue in the body to produce a missing or nonfunctioning protein. Based on the cells and genes of the individual the medicines that target the incorrect gene are produced. Most of the disease conditions can be cured or prevented by gene therapy medicine.
For instance, according to the NIH report in 2021, it is estimated that genetic therapy medicine management showed 30–40% complete response and 50–60% partial response with a total response rate of 90%–96% in different therapeutic uses. Thus, the above factors are expected to hold the segment in the dominant market share.
Geographical Analysis
North America is expected to hold a significant position in the global advanced therapy medicinal product (ATMP) market share
North America is expected to hold a dominant position in the market share due to the increase in genetic disorders. An increase in genetic disorders in the region is boosting research and paving the way for the development of new drugs.
For instance, According to the CDC report in 2022, Cystic fibrosis (CF) is a genetic disorder that causes problems with breathing and digestion. CF affects about 35,000 people in the United States. Approximately 1,000 new cases of CF are diagnosed each year in the U.S.
Additionally, researchers estimated that 18,000 males in the United States had hemophilia. Additionally, about two-thirds of these individuals received care in the U.S. network of specialized and comprehensive Hemophilia Treatment Centers (HTCs). Thus, the above factors are expected to drive the region’s market growth in the forecast period.
COVID-19 Impact Analysis
COVID-19 has had a moderate impact on the growth of the market. The R&D activities have been reduced during the COVID-19, this is due to the shift of the interest and need of the introduction of new drugs for the treatment of COVID-19. The supply chains have been interrupted during the lockdown period.
Market Segmentation
By Type
• Gene Therapy Medicines
• Somatic Cell Therapy Medicines
• Tissue Engineered Medicines
By Disease Indication
• Cancer
• Cardiovascular diseases
• Musculoskeletal
• Immune System and Inflammation
• Neurology
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include RHEACELL., BioTissue Technologies GmbH, Mukocell GmbH, Orchard Therapeutics plc., Kite Pharma EU B.V., Bristol-Myers Squibb Pharma EEIG, Novartis Europharm Limited, and Amgen Europe B.V. among others.
Why Purchase the Report?
• To visualize the global advanced therapy medicinal product (ATMP) market segmentation based on type, disease indication, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of advanced therapy medicinal product market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global advanced therapy medicinal product market report would provide approximately 47 tables, 48 figures, and 176 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Disease Indication
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increase in the number of research and developmental activities
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent regulations for the approvals
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Gene Therapy Medicines*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Somatic Cell Therapy Medicines
7.4. Tissue Engineered Medicines
8. By Disease Indication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
8.1.2. Market Attractiveness Index, By Disease Indication
8.2. Cancer *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular diseases
8.4. Musculoskeletal
8.5. Immune System and Inflammation
8.6. Neurology
8.7. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. RHEACELL. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. BioTissue Technologies GmbH
11.3. Mukocell GmbH
11.4. Orchard Therapeutics plc.
11.5. Kite Pharma EU B.V.
11.6. Bristol-Myers Squibb Pharma EEIG
11.7. Novartis Europharm Limited
11.8. Amgen Europe B.V.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

RHEACELL., 4.	Key Developments, BioTissue Technologies GmbH, Mukocell GmbH, Orchard Therapeutics plc., Kite Pharma EU B.V., Bristol-Myers Squibb Pharma EEIG, Novartis Europharm Limited, Amgen Europe B.V.

표 목록 (Tables)

List of Tables

Table 1 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2022-2031 (US$ Million)

Table 6 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2022-2031 (US$ Million)

Table 8 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Advanced Therapy Medicinal Product (ATMP) Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2022-2031 (US$ Million)

Table 11 North America Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2022-2031 (US$ Million)

Table 12 North America Advanced Therapy Medicinal Product (ATMP) Market Value, By Country, 2022-2031 (US$ Million)

Table 13 South America Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2022-2031 (US$ Million)

Table 14 South America Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2022-2031 (US$ Million)

Table 15 South America Advanced Therapy Medicinal Product (ATMP) Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2022-2031 (US$ Million)

Table 17 Europe Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2022-2031 (US$ Million)

Table 18 Europe Advanced Therapy Medicinal Product (ATMP) Market Value, By Country, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East & Africa Advanced Therapy Medicinal Product (ATMP) Market Value, By Type, 2022-2031 (US$ Million)

Table 23 Middle East & Africa Advanced Therapy Medicinal Product (ATMP) Market Value, By Disease Indication, 2022-2031 (US$ Million)

Table 24 RHEACELL.: Overview

Table 25 RHEACELL.: Product Portfolio

Table 26 RHEACELL.: Key Developments

Table 27 BioTissue Technologies GmbH: Overview

Table 28 BioTissue Technologies GmbH: Product Portfolio

Table 29 BioTissue Technologies GmbH: Key Developments

Table 30 Mukocell GmbH: Overview

Table 31 Mukocell GmbH: Product Portfolio

Table 32 Mukocell GmbH: Key Developments

Table 33 Orchard Therapeutics plc.: Overview

Table 34 Orchard Therapeutics plc.: Product Portfolio

Table 35 Orchard Therapeutics plc.: Key Developments

Table 36 Kite Pharma EU B.V.: Overview

Table 37 Kite Pharma EU B.V.: Product Portfolio

Table 38 Kite Pharma EU B.V.: Key Developments

Table 39 Bristol-Myers Squibb Pharma EEIG: Overview

Table 40 Bristol-Myers Squibb Pharma EEIG: Product Portfolio

Table 41 Bristol-Myers Squibb Pharma EEIG: Key Developments

Table 42 Novartis Europharm Limited: Overview

Table 43 Novartis Europharm Limited: Product Portfolio

Table 44 Novartis Europharm Limited: Key Developments

Table 45 Amgen Europe B.V.: Overview

Table 46 Amgen Europe B.V.: Product Portfolio

Table 47 Amgen Europe B.V.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 2 Global Advanced Therapy Medicinal Product (ATMP) Market Share, By Type, 2022 & 2031 (%)

Figure 3 Global Advanced Therapy Medicinal Product (ATMP) Market Share, By Disease Indication, 2022 & 2031 (%)

Figure 4 Global Advanced Therapy Medicinal Product (ATMP) Market Share, By Region, 2022 & 2031 (%)

Figure 5 Global Advanced Therapy Medicinal Product (ATMP) Market Y-o-Y Growth, By Type, 2022-2031 (%)

Figure 6 Gene Therapy Medicines Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 7 Somatic Cell Therapy Medicines Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 8 Tissue Engineered Medicines Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 9 Global Advanced Therapy Medicinal Product (ATMP) Market Y-o-Y Growth, By Disease Indication, 2022-2031 (%)

Figure 10 Cancer Disease Indication in Global Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 11 Cardiovascular diseases Disease Indication in Global Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 12 Musculoskeletal Disease Indication in Global Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 13 Immune System and Inflammation Disease Indication in Global Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 14 Neurology Disease Indication in Global Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 15 Others Disease Indication in Global Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 16 Global Advanced Therapy Medicinal Product (ATMP) Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 17 North America Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 18 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 19 Europe Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 20 South America Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 21 Middle East and Africa Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 22 North America Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 23 North America Advanced Therapy Medicinal Product (ATMP) Market Share, By Type, 2022 & 2031 (%)

Figure 24 North America Advanced Therapy Medicinal Product (ATMP) Market Share, By Disease Indication, 2022 & 2031 (%)

Figure 25 North America Advanced Therapy Medicinal Product (ATMP) Market Share, By Country, 2022 & 2031 (%)

Figure 26 South America Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 27 South America Advanced Therapy Medicinal Product (ATMP) Market Share, By Type, 2022 & 2031 (%)

Figure 28 South America Advanced Therapy Medicinal Product (ATMP) Market Share, By Disease Indication, 2022 & 2031 (%)

Figure 29 South America Advanced Therapy Medicinal Product (ATMP) Market Share, By Country, 2022 & 2031 (%)

Figure 30 Europe Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 31 Europe Advanced Therapy Medicinal Product (ATMP) Market Share, By Type, 2022 & 2031 (%)

Figure 32 Europe Advanced Therapy Medicinal Product (ATMP) Market Share, By Disease Indication, 2022 & 2031 (%)

Figure 33 Europe Advanced Therapy Medicinal Product (ATMP) Market Share, By Country, 2022 & 2031 (%)

Figure 34 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 35 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Share, By Type, 2022 & 2031 (%)

Figure 36 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Share, By Disease Indication, 2022 & 2031 (%)

Figure 37 Asia-Pacific Advanced Therapy Medicinal Product (ATMP) Market Share, By Country, 2022 & 2031 (%)

Figure 38 Middle East & Africa Advanced Therapy Medicinal Product (ATMP) Market Value, 2022-2031 (US$ Million)

Figure 39 Middle East & Africa Advanced Therapy Medicinal Product (ATMP) Market Share, By Type, 2022 & 2031 (%)

Figure 40 Middle East & Africa Advanced Therapy Medicinal Product (ATMP) Market Share, By Disease Indication, 2022 & 2031 (%)

Figure 41 RHEACELL.: Financials

Figure 42 BioTissue Technologies GmbH: Financials

Figure 43 Mukocell GmbH: Financials

Figure 44 Orchard Therapeutics plc.: Financials

Figure 45 Kite Pharma EU B.V.: Financials

Figure 46 Bristol-Myers Squibb Pharma EEIG: Financials

Figure 47 Novartis Europharm Limited: Financials

Figure 48 Amgen Europe B.V.: Financials

글로벌 첨단 치료 의약품(ATMP) 시장 – 2023-2030

Global Advanced Therapy Medicinal Product (ATMP) Market - 2023-2030